New biosimilar policy benefits industry, not patients: AMA


Strategies to drive up prescribing of biosimilar medicines in a bid to save PBS dollars are proving unpopular with clinicians, with the AMA opposing two new proposals. The government is consulting the medical world on a range of ‘uptake drivers’, which according to an AMA submission include plans to insert a ‘restriction’ note in the ...


Already a member? Login to keep reading


OR
© 2017 the limbic